

Catheter Ablation can delay Atrial Fibrillation Progression by 10x than drug therapy

30 September 2020 | News

Patients treated with RF catheter ablation experienced fewer arrhythmia recurrences over three years of follow-up.



Please refer to corresponding references in report.

Biosense Webster.
an Johnson & Johnson Medical Devices Company

Biosense Webster, Inc., part of the Johnson & Johnson Medical Devices Companies*, has published a report, [Atrial Fibrillation: An APAC Guide to Patient Impact, Disease Management, and Treatment Outcomes](#), examining available

treatment options for Atrial Fibrillation (AF) across the Asia Pacific and the long-term impact on clinical, patient, and economic outcomes.

In Asia Pacific, it is estimated that 16 million people are affected by AF -- a condition characterized by an irregular and often fast heart rhythm. This irregular heart rhythm, known as an arrhythmia, can lead to serious health complications including blood clots and an increased risk of heart failure, stroke, and death. However, early detection and access to treatment can significantly improve outcomes, potentially increasing the overall quality and expectancy of the patient's life.

Biosense Webster's latest report further affirmed the clinical and economic efficacy of catheter ablation with data showing:

- Significant improvements on patients' quality of life (37% for catheter ablation vs. 18% for AADs)
- Up to 94% freedom from arrhythmia recurrence at one year
- 30% fewer AF-related complications such as death, stroke, cardiac arrest, and cardiovascular hospitalization
- Cost-effectiveness compared to drug therapy over the long-term